# **TEST REPORT**

8605 SW Creekside Place Beaverton, OR 97008 Phone: 503-466-2445 Fax: 503-466-1636



#### # 2018 08 08 222 S

**Ordering Provider:** Getuwell Clinic John Getuwell. MD

#### Samples Received 08/08/2018

**Report Date** 08/10/2018 **Samples Collected** Saliva - 08/05/18 06:05 Saliva - 08/05/18 13:00 Saliva - 08/05/18 18:40 Saliva - 08/05/18 21:46

## Patient Name: Saliva Profile III Patient Phone Number: 555 555 5555

<b>Gender</b> Female	Last Menses Unspecified	<b>Height</b> Unspecified	Waist Unspecified	
<b>DOB</b> 7/13/1958 (60 yrs)	<b>Menses Status</b> Postmenopausal	<b>Weight</b> Unspecified		
TEST NAME	RESULTS   08/05/	18 07/21/1	7 01/25/17	RANGE
Salivary Steroids				
Estradiol	2.2	2.0		0.8-12 pg/mL Estrogen Rplcmnt (optimal 1.3-3.3)
Progesterone	833	974		200-3000 pg/mL Topical, Troche, Vag Pg (10-30mg)
Ratio: Pg/E2	379	487		Optimal: 100-500 when E2 1.3-3.3 pg/mL
Testosterone	33	32		16-55 pg/mL (Age Dependent)
DHEAS	1.5 L	1.6 <b>L</b>	4.4	2-23 ng/mL (Age Dependent)
Cortisol	7.0	4.2	3.1 <b>L</b>	3.7-9.5 ng/mL (morning)
Cortisol	2.2	1.1 L	1.8	1.2-3.0 ng/mL (noon)
Cortisol	0.9	0.6	1.0	0.6-1.9 ng/mL (evening)
Cortisol	0.9	1.3 <b>H</b>	0.8	0.4-1.0 ng/mL (night)

<dL = Less than the detectable limit of the lab. N/A = Not applicable; 1 or more values used in this calculation is less than the detectable limit. H = High. L = Low.</p>

#### Therapies

08/05/2018: 1mg topical Biestrogen (80/20 E3 + E2) (compounded) (24 Hours Last Used) 30mg topical Progesterone (compounded) (12 Hours Last Used) 0.5mg topical Testosterone (compounded) (24 Hours Last Used) topical DHEA (compounded) (24 Hours Last Used)

07/21/2017: topical Estrogen (type not indicated) (compounded) (1 Days Last Used) topical Progesterone (compounded) (1 Days Last Used) oral DHEA (OTC) (1 Days Last Used) oral Pregnenolone (OTC) (1 Days Last Used) Siberian Ginseng Zinc

01/25/2017: 0.25mg topical Biestrogen (80/20 E3 + E2) (compounded) (1 Days Last Used); 50mg topical Progesterone (compounded) (1 Days Last Used); 0.4mg topical Testosterone (compounded) (1 Days Last Used); 8mg topical DHEA (compounded) (1 Days Last Used); 5000IU oral Vitamin D3 (OTC) (1 Days Last Used); sublingual (SL) Melatonin (OTC) (1 Days Last Used)







1 of 4

### Graphs

Disclaimer: Graphs below represent averages for healthy individuals not using hormones. Supplementation ranges may be higher. Please see supplementation ranges and lab comments if results are higher or lower than expected.

Average ▼▲ Off Graph





03:00 06:00 09:00 12:00 15:00 18:00 21:00 00:00 03:00 Time of Day

CLIA Lic # 38D0960950 9/14/2018 10:27:13 AM



# **TEST REPORT |** Patient Reported Symptoms

Disclaimer: Symptom Categories below show percent of symptoms self-reported by the patient compared to total available symptoms for each category. For detailed information on category breakdowns, go to www.zrtlab.com/patient-symptoms.

SYMPTOM CATEGORIES	RESULTS   08/05/18	07/21/17	01/25/17		
Estrogen / Progesterone Deficiency	2%	14%	17%		
Estrogen Dominance / Progesterone Deficiency	0%	3%	2%		
Low Androgens (DHEA/Testosterone)	4%	23%	15%		
High Androgens (DHEA/Testosterone)	10%	10%	10%		
Low Cortisol	5%	23%	9%		
High Cortisol	2%	20%	19%		
Hypometabolism	0%	9%	6%		
•••		2%			
Metabolic Syndrome	2%	2%	2%		
SYMPTOM CHECKLIST	1 2 3				
Aches and Pains					
Acne					
Allergies					
Anxious					
Bleeding Changes					
Blood Pressure High					
Blood Pressure Low					
Blood Sugar Low					
Body Temperature Cold					
Bone Loss					
Breast Cancer					
Breasts - Fibrocystic					
Breasts - Tender					
Chemical Sensitivity					
Cholesterol High					
Constipation					
Depressed					
Fatigue - Evening					
Fatigue - Morning					
Fibromyalgia					
Foggy Thinking					
Goiter					
Hair - Dry or Brittle					
Hair - Increased Facial or Body					
Hair - Scalp Loss					
Headaches					
Hearing Loss					
Heart Palpitations					
Hoarseness					
Hot Flashes					
Incontinence					
Infertility					
Irritable					
Libido Decreased					
Memory Lapse					
Mood Swings					
Muscle Size Decreased					
Nails Breaking or Brittle					
Nervous					
Night Sweats					
Numbness - Feet or Hands					
CLIA Lic # 38D0960950 The above results and comments are for informationa purposes only and are not to be construed as medical advice. Please consult your healthcare practitioner for	Nand J. Sava. Laboratory Direc	tor ADMAllisteenD.	Alison McAllister, ND. (Ordering Provider unless otherwise specified on page 1)		

purposes only and are not to be construed as medical advice. Please consult your healthcare practitioner for diagnosis and treatment.

Navid J. Java. Laboratory Director

otherwise specified on page 1)

## **TEST REPORT** | Patient Reported Symptoms continued

SYMPTOM CHECKLIST	1	2	3			
Pulse Rate Slow						
Rapid Aging						
Rapid Heartbeat						
Skin Thinning						
Sleep Disturbed						
Stamina Decreased						
Stress						
Sugar Cravings						
Sweating Decreased						
Swelling or Puffy Eyes/Face						
Tearful						
Triglycerides Elevated						
Urinary Urge Increased						
Uterine Fibroids						
Vaginal Dryness						
Water Retention						
Weight Gain - Hips						
Weight Gain - Waist						

## Lab Comments

Estradiol is within the observed range for physiological topical bi-estrogen replacement therapy, and within the observed range seen in most premenopausal women (1.3-3.3 pg/ml) without symptoms of estrogen imbalance. Symptoms of estrogen imbalance are minimal at this time, based on self-reporting, indicating that dosing and delivery of estrogens is optimal.

Progesterone is within luteal range with physiological (10-30 mg) topical progesterone supplementation. Progesterone is well balanced with estradiol (optimal Pg/E2 ratio) and symptoms of estrogen/progesterone imbalance (deficiency and excess) are minimal.

Testosterone is within expected range with physiological topical testosterone therapy. Symptoms of androgen deficiency and/or excess are minimal, indicating that dosing and delivery is appropriate and optimal.

DHEAS is lower than range with topical DHEA supplementation. Topical DHEA therapy increases circulating levels of DHEA but has little impact on salivary or serum levels of DHEAS. Topical DHEA therapy bypasses the liver, where sulfation of DHEA occurs. In contrast, oral DHEA supplementation results in a marked rise in DHEAS since sulfation occurs primarily in the liver. DHEAS may also be lower due to low levels of sulfotransferase (an enzyme that sulfates DHEA to form DHEAS) or higher levels of sulfatase (an enzyme that removes the sulfate from DHEAS, converting it back to DHEA, and is higher with conditions of inflammation).

Cortisol is within expected range throughout most of the day but is over 0.8 at night. While levels up to 1.0 are normal, symptoms of high cortisol may be experienced at levels greater than 0.8 in some people. A higher night cortisol suggests some form of adrenal stressor (emotional/ physical-surgery, injury or disease causing inflammation/dietary-starvation/low blood glucose from dysglycemia/microbial-bacterial, fungal, or viral infections). Acute effects of a high cortisol are usually associated with agitation-irritability, anxiety, and sleep disturbances. However, when the stressor has been chronic over a prolonged period of time (months/years) this leads to conditions such as weight gain in the waist, muscle and bone loss, depression, and immune suppression. If the high night cortisol is associated with symptoms characteristic of chronic high cortisol consider means to identify and eliminate the stressor. Because chronic stressors and associated high night cortisol can have serious long term adverse effects on health and well being, it is important to develop strategies to identify and eliminate or reduce the stressors. For additional information about adrenal dysfunction and strategies for adrenal support and lowering stress/cortisol levels the following books and journal articles are worth reading: "Adrenal Fatigue; The 21st Century Stress Syndrome", by James L. Wilson, N.D., D.C., Ph.D.; "The Cortisol Connection", by Shawn Talbott, Ph.D.; "The End of Stress As We Know It" by Bruce McEwen; "Phosphatidylserine", by Paris Kidd, Ph.D.; "The influence of Phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor", Benton et al., Nutritional Neuroscience 4; 169-178, 2001.

CLIA Lic # 38D0960950 /14/2018 10:27:13 AN

The above results and comments are for informational purposes only and are not to be construed as medical advice. Please consult your healthcare practitioner for diagnosis and treatment



David T. Zava, Ph.D.

4 of 4